Our analysis suggests that the loss of TP53 or RB1 function may result in antitumor immunosuppression in HCC, consistent with the findings shown in other cancers (Jiang et al., 2018; Xiao et al., 2018; Lyu et al., 2019). This evidence concerns the gene TP53 and hepatocellular carcinoma.